Mostly based on the experience of melanoma treatment and the recent clinical trials in adult [66,67] and pediatric (NCT02684058) settings, targeted therapies will rely both on the exact nature of the activating BRAF alteration and on the possible additional alterations. Here, BRAF is linked to melanoma.